Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Lena Rubi et al.
Anti-addiction Drug Ibogaine Prolongs the Action Potential
in Human Induced Pluripotent Stem Cell-Derived
Cardiomyocytes
Lena Rubi1 • Daniel Eckert1 • Stefan Boehm1 • Karlheinz Hilber1 •
Xaver Koenig1
Published online: 28 March 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Ibogaine is a plant alkaloid used as anti-ad-
diction drug in dozens of alternative medicine clinics
worldwide. Recently, alarming reports of life-threatening
cardiac arrhythmias and cases of sudden death associated
with the ingestion of ibogaine have accumulated. Using
whole-cell patch clamp recordings, we assessed the effects
of ibogaine and its main metabolite noribogaine on action
potentials in human ventricular-like cardiomyocytes
derived from induced pluripotent stem cells. Therapeutic
concentrations of ibogaine and its long-lived active
metabolite noribogaine significantly retarded action
potential repolarization in human cardiomyocytes. These
findings represent the first experimental proof that ibogaine
application entails a cardiac arrhythmia risk for humans. In
addition, they explain the clinically observed delayed
incidence of cardiac adverse events several days after
ibogaine intake. We conclude that therapeutic concentra-
tions of ibogaine retard action potential repolarization in
the human heart. This may give rise to a prolongation of
the QT interval in the electrocardiogram and cardiac
arrhythmias.
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Introduction
The plant alkaloid ibogaine exerts convincing anti-addic-
tive properties, but has never been approved as anti-ad-
diction medication [1, 2]. Largely because of ibogaine’s
status as banned substance in the USA since 1970, the
further development of the alkaloid’s use in addiction
therapy took place outside conventional clinical and med-
ical settings [1]. Ten years ago, Frank Vocci, at that time
director of anti-addiction drug development at the National
Institute on Drug Abuse, termed ibogaine therapy ‘‘a vast,
uncontrolled experiment’’ [3]. Nevertheless, the ibogaine
‘‘medical subculture’’ has continued to grow, with dozens
of alternative medicine clinics operating worldwide [1, 2].
Recently, alarming reports of life-threatening cardiac
arrhythmias and sudden death cases [4–12], temporally
associated with the ingestion of ibogaine, have accumu-
lated. We [13–16] and others [17] hypothesized that these
were related to the drug’s propensity to block human ether-
a-go-go-related gene (hERG) potassium channels in the
heart, which can result in retardation of ventricular action
potential (AP) repolarization and prolongation of the QT
interval in the electrocardiogram (ECG) [18]. QT prolon-
gation—indeed observed in people after ibogaine intake
(e.g. [2, 4, 5])—is known to be associated with an
increased risk of life-threatening torsade de pointes (TdP)
arrhythmias [18].
Up to now, the inhibition of currents through heterolo-
gously expressed hERG channels by ibogaine (IC50 value,
drug concentration needed for half-maximum inhibi-
tion = 3–4 lM [13, 14, 17]) remains the sole experimental
evidence for the drug’s proarrhythmic potential in humans;
data on human cardiomyocytes are still lacking. Moreover,
two observations have cast reasonable doubts on ibogaine’s
cardiotoxic effects: first, although hERG channel inhibition
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should retard AP repolarization, the drug significantly
shortens AP duration in guinea pig ventricular cardiomy-
ocytes [14]), a well-established model system for human
myocytes. Secondly, cardiac adverse events in humans
often occur many hours or even several days after ibogaine
intake [2], albeit the drug has a half-life in human plasma
of 4–7 h only [2, 19].
Methods
Details of our experimental procedures are described
elsewhere [14]. Action potentials (APs) were recorded
from ‘‘ventricular-like’’ human induced pluripotent stem
cell-derived cardiomyocytes (hiPS-CM, Cellectis, Sweden)
in the current-clamp mode of the whole-cell patch clamp
technique at room temperature (22 ± 1 C). Cardiomy-
ocytes were classified as ventricular-like if their APs
showed a distinct ‘‘shoulder’’ (plateau or flat repolarization
phase) prior to a final steep phase of repolarization. APs
were elicited at 1 Hz by rectangular current pulses of 4 ms
duration at 125 % threshold level. The pipette solution
contained 10 mM NaCl, 140 mM KCl, 2 mM EGTA,
1 mM MgCl2, 0.1 mM Na-GTP, 5 mM Mg-ATP, 10 mM
Hepes, and pH = 7.2 adjusted with KOH. The cells were
bathed in 140 mM NaCl, 4 mM KCl, 2 mM CaCl2, 2 mM
MgCl2, 5 mM HEPES, 5 mM glucose, and pH = 7.4
adjusted with NaOH.
Whole-cell currents through hERG potassium channels
heterologously expressed in TSA-201 cells were recorded
as in our previous studies [13, 14].
Results and Discussion
By assessing the effects of ibogaine and its main metabolite
noribogaine on APs in cardiomyocytes derived from
human induced pluripotent stem cells, we provide the first
experimental proof that ibogaine application does indeed
entail a cardiac risk for humans, and we further unravel the
Fig. 1 Ibogaine and noribogaine impair the electrophysiology of the
human heart. a Action potential (AP) recordings from human
cardiomyocytes under control conditions and after superfusion with
bath solution containing 3 lM ibogaine (ibo, top) or noribogaine
(noribo, bottom). b Analysis of the retardation of AP repolarization by
ibogaine and noribogaine. APD90 (mean ± SD, n = 6–16), AP
duration at 90 % repolarization. **(p\ 0.01) and ***(p\ 0.001),
significantly different from control (paired Student’s t test performed
on raw data prior to normalization). The absolute APD90 values (in
ms) were 282 ± 147 for control and 322 ± 165 for 3 lM ibogaine, as
well as 264 ± 137 for control and 305 ± 155 for 3 lM noribogaine.
APD50, AP duration at 50 % repolarization, was neither altered by
3 lM ibogaine (p = 0.64) nor noribogaine (p = 0.39). c Proposed
mechanism of cardiac arrhythmia generation after ibogaine intake.
The cartoon summarizes the causal sequence of drug effects at the ion
channel, cellular, and organ level: both ibogaine and noribogaine, the
latter generated from ibogaine by CYP2D6 enzymes in the liver [21,
22], block hERG potassium channels and thereby retard the repolar-
ization phase of the ventricular AP. As a consequence, the QT interval
in the ECG gets prolonged, and finally, cardiac arrhythmias emerge
216 Cardiovasc Toxicol (2017) 17:215–218
123
mystery of the surprising longevity of the drug’s potential
to cause arrhythmias. Thus, Fig. 1 shows that 3 lM ibo-
gaine, a concentration at the IC50 value for hERG channel
inhibition [13, 14, 17] and well within the free plasma
concentration range reached in humans after drug intake
(up to 11 lM) [14], significantly prolongs the AP and
flattens its repolarization phase in human cardiomyocytes
[Fig. 1a (top), b]. This effect was fully reversible after
washout of the drug (data not shown). Similar to ibogaine,
also its long-lived active metabolite noribogaine (plasma
half-life, 28–49 h [20]) prolonged the human cardiac AP
[Fig. 1a (bottom), b]. This observation goes along with
noribogaine’s inhibitory action on hERG potassium chan-
nels (IC50 = 3 lM: Fig. 2; [17]), which very closely
resembles hERG inhibition by ibogaine [13, 14, 17]. It
further provides an explanation for the delayed incidence
of cardiac adverse events, which may occur even several
days after ibogaine intake.
Based on these unprecedented findings, we propose the
following sequence to explain the cardiotoxicity associated
with ibogaine ingestion (Fig. 1c): (1) inhibition of repolar-
izing hERG potassium channels by ibogaine and its
metabolite noribogaine, followed by (2) retardation of ven-
tricular AP repolarization, and finally (3) prolongation of the
QT interval in the electrocardiogram (ECG), ultimately
paving the way for life-threatening TdP arrhythmias. Because
of its long half-life in human plasma [20], we consider
noribogaine, rather than ibogaine itself, as the crucial mole-
cule triggering this sequence of deleterious events.
Since drug-induced AP prolongation in ventricular car-
diomyocytes directly correlates with prolonged QT inter-
vals in the ECG [18], the actions of ibogaine and
noribogaine reported herein can explain previously pub-
lished case reports of QT interval prolongation triggered by
single doses of ibogaine and lasting several days (e.g. [2, 4,
5]). hERG channel inhibition and concomitant retardation
of AP repolarization caused by therapeutic plasma con-
centrations of any drug are well-known predictors of an
increased risk for TdP arrhythmias and sudden cardiac
death [18]. Moreover, formerly approved drugs with ibo-
gaine-like effects on in vitro cardiac electrophysiology, e.g.
cisapride and astemizole, have been withdrawn from the
market because of the unbearable TdP arrhythmia risk
associated with their application [18].
We therefore conclude that the use of ibogaine, at doses
currently administered to drug addicts, must be considered
a dangerous practice. Arrhythmias may emerge due to
drug-induced QT interval prolongation resulting from
retarded cardiac action potential repolarization.
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